<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="article-commentary"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Cycle</journal-id><journal-id journal-id-type="iso-abbrev">Cell Cycle</journal-id><journal-id journal-id-type="publisher-id">CC</journal-id><journal-title-group><journal-title>Cell Cycle</journal-title></journal-title-group><issn pub-type="ppub">1538-4101</issn><issn pub-type="epub">1551-4005</issn><publisher><publisher-name>Landes Bioscience</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23588071</article-id><article-id pub-id-type="pmc">3674056</article-id><article-id pub-id-type="publisher-id">2013FT0930</article-id><article-id pub-id-type="doi">10.4161/cc.24579</article-id><article-id pub-id-type="pii">24579</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorials: Cell Cycle Features</subject></subj-group></article-categories><title-group><article-title>The p53 family and VEGF regulation</article-title><subtitle>&#x0201c;It&#x02019;s complicated&#x0201d;</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Farhang Ghahremani</surname><given-names>Morvarid</given-names></name><xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="A2">
<sup>2</sup>
</xref><xref ref-type="author-notes" rid="afn0">
<sup>&#x02020;</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Goossens</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="A2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Haigh</surname><given-names>Jody J.</given-names></name><xref ref-type="aff" rid="A1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="A2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="A1"><label>1</label>Vascular Cell Biology Unit; Department for Molecular Biomedical Research; VIB; Ghent, Belgium</aff><aff id="A2"><label>2</label>Department for Biomedical Molecular Biology; Ghent University; Ghent, Belgium</aff></contrib-group><author-notes><fn id="afn0"><label>&#x02020;</label><p>Current affiliation: Molecular Signal Transduction in Inflammation Unit; Department for Molecular Biomedical Research; VIB; Ghent, Belgium</p></fn><corresp id="cor1"><label>*</label>Correspondence to: Jody J. Haigh, Email: <email xlink:href="jody.haigh@dmbr.ugent.be">jody.haigh@dmbr.ugent.be</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>5</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>11</day><month>4</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>4</month><year>2013</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>12</volume><issue>9</issue><fpage>1331</fpage><lpage>1332</lpage><history><date date-type="received"><day>29</day><month>3</month><year>2013</year></date><date date-type="accepted"><day>03</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 Landes Bioscience</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>HIF-1&#x003b1;</kwd><kwd>MEFs</kwd><kwd>VEGF</kwd><kwd>angiogenesis</kwd><kwd>cancer</kwd><kwd>hypoxia</kwd><kwd>p21</kwd><kwd>p53</kwd><kwd>p63</kwd><kwd>p73</kwd></kwd-group></article-meta></front><body><p>Tumor-associated angiogenesis supplies the growing tumor with the necessary oxygen and nutrients and is as well critical for the progression and metastatic spread of the disease. Therefore, suppressing tumor-associated angiogenesis has often been proposed as a promising antitumor therapy. Vascular endothelial growth factor (VEGF) is one of the most recognized endothelial growth factors involved in several aspects of cancer progression, and it is not surprising that its synergy and interactions with the well-known tumor suppressor gene p53 is of keen interest.</p><p>Until recently it was accepted that wild-type p53 indirectly represses VEGF expression by interaction and inhibition of transcription factors such as SP1,<xref ref-type="bibr" rid="R1"><sup>1</sup></xref> E2F<sup>2</sup>. New evidence using primary mouse embryonic fibroblasts (MEFs) indicate that the regulation of the VEGF promoter by p53 is more complex than was originally proposed. In addition to the indirect repressive role of p53 on VEGF promoter activity, it seems that p53 is also required for VEGF induction during the initial phases of hypoxia.<xref ref-type="bibr" rid="R3"><sup>3</sup></xref> A highly conserved unconventional but functional p53-binding site adjacent to the main HIF-1&#x003b1; binding site was identified within the VEGF promoter and shown to be essential for this p53-mediated VEGF induction. Saturation of the cells with stabilized p53, e.g., after doxorubicin treatment, seemingly is not enough to induce VEGF promoter activation and likely requires the hypoxia-dependent HIF-1&#x003b1;/p53 complex.<xref ref-type="bibr" rid="R3"><sup>3</sup></xref></p><p>In all these experiments, full-length wild-type p53 was analyzed. However, we should also take into consideration that the p53 gene can theoretically produce at least 20 alternative isoforms.<xref ref-type="bibr" rid="R4"><sup>4</sup></xref> Among these potential variants, the &#x00394;133p53 isoform is of significant interest. This isoform lacks the transactivation domain (TA) and part of the DNA-binding domain and has been suggested to play an oncogenic role.<xref ref-type="bibr" rid="R4"><sup>4</sup></xref> It was demonstrated that &#x00394;133p53 is responsible for strong angiogenesis stimulation in glioblastomas and contributes to tumor progression.<xref ref-type="bibr" rid="R5"><sup>5</sup></xref> The expression ratio between p53 and &#x00394;133p53 was suggested to regulate angiogenesis in human glioblastoma U87 cells by differentially modulating expression of anti/pro-angiogenic genes. However, &#x00394;133p53 does not seem to affect VEGF expression,<xref ref-type="bibr" rid="R5"><sup>5</sup></xref> and the molecular mechanisms behind &#x00394;133p53&#x02019;s ability to modulate pro/anti-angiogenic genes remains to be elucidated.</p><p>In addition, the other two p53 family members, p63 and p73, have similar structures and mechanisms of regulation and are similarly relevant concerning their effects on angiogenesis. In cell lines that contain wild-type p53, p73 seems to increase VEGF expression, exerting a pro-angiogenic phenotype.<xref ref-type="bibr" rid="R6"><sup>6</sup></xref> It is not clear how this regulation occurs, since the VEGF promoter is only partially affected, and the half-life of the VEGF mRNA is not influenced. On the other hand, in cells with deleted or mutated p53, p73 acts as a repressor of VEGF transcription. This effect is mediated by repression at the promoter level at a 35 bp region containing SP1 binding sites,<xref ref-type="bibr" rid="R7"><sup>7</sup></xref> the same region previously described to be inhibited by p53.<xref ref-type="bibr" rid="R1"><sup>1</sup></xref> Although in the case of p73, a molecular mechanism has not been described for its ability to inhibit VEGF expression, it is likely that given its similar structure, p73 also sequesters SP1 away from its positive role on VEGF promoter transcriptional regulation.</p><p>The two major isoforms of p63, TAp63&#x003b3; and dNp63&#x003b1;, have been shown to have opposite effects on the VEGF promoter. Similar to p53, TAp63&#x003b3; represses VEGF expression by interacting with HIF-1&#x003b1; and mediating its proteasomal degradation. Additionally, TAp63&#x003b3; binds to SP1 and prevents its association with the VEGF promoter. Conversely, dNp63&#x003b1; seems to have a dominant-negative effect on p53 and TAp63&#x003b3; and induces VEGF expression by stabilizing HIF-1&#x003b1; and possibly contributing to the recruitment of p300/CBP to promote target gene expression. A 149 bp promoter region containing the HIF-1&#x003b1; binding site seems to be a crucial element for dNp63&#x003b1; to activate VEGF expression.<xref ref-type="bibr" rid="R8"><sup>8</sup></xref></p><p>It is known that TAp73 and TAp63 interact with p53 response elements and are able to induce some p53 target genes.<xref ref-type="bibr" rid="R4"><sup>4</sup></xref> Now that we have shown that there is a functional p53 binding site within the VEGF promoter,<xref ref-type="bibr" rid="R3"><sup>3</sup></xref> there is a possibility that both p73 and dNp63&#x003b1; are also able to bind to this region and influence VEGF expression, especially in the case of dNp63&#x003b1;, where not only does it interact with HIF-1&#x003b1;, but the promoter region containing the p53 site is crucial for its activation role (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>). p21 is also among the target genes of p73 and p63. Given the observation that VEGF repression by p53 is dependent on the p21 pathway,<xref ref-type="bibr" rid="R3"><sup>3</sup></xref> the probability that p63 and p73 can also repress VEGF via p21 pathway modulation is also high (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>).</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><caption><p><bold>Figure&#x000a0;1.</bold> Schematic representation of VEGF promoter regulation by p53 family members and their isoforms. We have shown that p53 can positively regulate VEGF expression during the initial phases of hypoxia by direct binding to conserved sites in the VEGF promoter.<xref ref-type="bibr" rid="R3"><sup>3</sup></xref> It remains to be determined if p73 and dNp63 can synergistically act with HIF-1&#x003b1; in positively regulating VEGF expression during hypoxia by directly binding to this conserved site. We have also demonstrated that p53 can indirectly repress VEGF expression during continued hypoxic challenge that is genetically dependent on the presence of p21.<xref ref-type="bibr" rid="R3"><sup>3</sup></xref> Here it remains to be determined whether p73 and TAp63&#x02019;s negative effects on VEGF expression are dependent on a functional p21-E2F pathway.</p></caption><graphic xlink:href="cc-12-1331-g1"/></fig><p>The dynamic regulation of VEGF by the p53 family members makes its regulation complex, especially given the fact that all three transcription factors are both able to induce and repress VEGF, which appears to be dependent on cellular context and stimulus. Due to their similar structure and targets, it is important to consider if the newly discovered mechanisms for p53 regulation of VEGF<xref ref-type="bibr" rid="R3"><sup>3</sup></xref> during hypoxia also apply to the two other family members. Also, the question as to whether they can substitute or compensate for each other and how this will ultimately affect the strategies used to target tumor angiogenesis needs further clarification.</p></body><back><fn-group><fn fn-type="other"><p>Previously published online: <ext-link ext-link-type="uri" xlink:href="http://www.landesbioscience.com/journals/cc/article/24579/">www.landesbioscience.com/journals/cc/article/24579</ext-link></p></fn></fn-group><notes><p>
<related-article id="d37e281" related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.1038/cdd.2013.12" journal-id="Cell Death Differ">
<person-group person-group-type="author"><name><surname>Farhang Ghahremani</surname><given-names>M</given-names></name><name><surname>Goossens</surname><given-names>S</given-names></name><name><surname>Nittner</surname><given-names>D</given-names></name><name><surname>Bisteau</surname><given-names>X</given-names></name><name><surname>Bartunkova</surname><given-names>S</given-names></name><name><surname>Zwolinska</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway</article-title>
<source>Cell Death Differ</source>
<year>2013</year>
<pub-id pub-id-type="doi">10.1038/cdd.2013.12</pub-id>
</related-article>
</p></notes><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>S</given-names></name><name><surname>Datta</surname><given-names>K</given-names></name><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name></person-group><article-title>Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>6952</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11559575</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>G</given-names></name><name><surname>Kishore</surname><given-names>R</given-names></name><name><surname>Dolan</surname><given-names>CM</given-names></name><name><surname>Silver</surname><given-names>M</given-names></name><name><surname>Wecker</surname><given-names>A</given-names></name><name><surname>Luedemann</surname><given-names>CN</given-names></name><etal/></person-group><article-title>Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>11015</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1073/pnas.0509533103</pub-id><pub-id pub-id-type="pmid">16835303</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhang Ghahremani</surname><given-names>M</given-names></name><name><surname>Goossens</surname><given-names>S</given-names></name><name><surname>Nittner</surname><given-names>D</given-names></name><name><surname>Bisteau</surname><given-names>X</given-names></name><name><surname>Bartunkova</surname><given-names>S</given-names></name><name><surname>Zwolinska</surname><given-names>A</given-names></name><etal/></person-group><article-title>p53 promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway</article-title><source>Cell Death Differ</source><year>2013</year><comment>Epub Ahead of Print</comment><pub-id pub-id-type="doi">10.1038/cdd.2013.12</pub-id><pub-id pub-id-type="pmid">23449391</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Zaika</surname><given-names>E</given-names></name><name><surname>Zaika</surname><given-names>A</given-names></name></person-group><article-title>p53 Family: Role of Protein Isoforms in Human Cancer</article-title><source>J Nucleic Acids</source><year>2012</year><volume>2012</volume><fpage>687359</fpage><pub-id pub-id-type="doi">10.1155/2012/687359</pub-id><pub-id pub-id-type="pmid">22007292</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>H</given-names></name><name><surname>Garmy-Susini</surname><given-names>B</given-names></name><name><surname>Ainaoui</surname><given-names>N</given-names></name><name><surname>Van Den Berghe</surname><given-names>L</given-names></name><name><surname>Peurichard</surname><given-names>A</given-names></name><name><surname>Javerzat</surname><given-names>S</given-names></name><etal/></person-group><article-title>The p53 isoform, &#x00394;133p53&#x003b1;, stimulates angiogenesis and tumour progression</article-title><source>Oncogene</source><year>2012</year><comment>Epub Ahead of Print</comment><pub-id pub-id-type="doi">10.1038/onc.2012.242</pub-id><pub-id pub-id-type="pmid">22733133</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vikhanskaya</surname><given-names>F</given-names></name><name><surname>Bani</surname><given-names>MR</given-names></name><name><surname>Borsotti</surname><given-names>P</given-names></name><name><surname>Ghilardi</surname><given-names>C</given-names></name><name><surname>Ceruti</surname><given-names>R</given-names></name><name><surname>Ghisleni</surname><given-names>G</given-names></name><etal/></person-group><article-title>p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><fpage>7293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1204896</pub-id><pub-id pub-id-type="pmid">11704858</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salimath</surname><given-names>B</given-names></name><name><surname>Marm&#x000e9;</surname><given-names>D</given-names></name><name><surname>Finkenzeller</surname><given-names>G</given-names></name></person-group><article-title>Expression of the vascular endothelial growth factor gene is inhibited by p73</article-title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>3470</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203672</pub-id><pub-id pub-id-type="pmid">10918605</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senoo</surname><given-names>M</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Habu</surname><given-names>S</given-names></name></person-group><article-title>TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>2455</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205330</pub-id><pub-id pub-id-type="pmid">11971180</pub-id></element-citation></ref></ref-list></back></article>